.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
US Department of Justice
Harvard Business School
Federal Trade Commission
Deloitte
Merck
Citi
Moodys
Express Scripts
Boehringer Ingelheim

Generated: July 23, 2017

DrugPatentWatch Database Preview

Genzyme Corp Company Profile

« Back to Dashboard

What is the competitive landscape for GENZYME CORP, and when can generic versions of GENZYME CORP drugs launch?

GENZYME CORP has five approved drugs.

There are five US patents protecting GENZYME CORP drugs.

There are one hundred and eleven patent family members on GENZYME CORP drugs in thirty-nine countries.

Summary for Applicant: Genzyme Corp

Patents:5
Tradenames:4
Ingredients:4
NDAs:5
Drug Master File Entries: (click here to view)5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes7,196,205► SubscribeY ► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
INJECTABLE;INJECTION021027-002Apr 6, 2000APRXYesNo► Subscribe► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYes8,067,427► SubscribeY ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYesRE42353► SubscribeYY ► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes6,916,802► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Genzyme Corp

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-002Apr 23, 20045,602,116► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-002Apr 23, 20045,869,473► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
INJECTABLE;INJECTION021027-002Apr 6, 20005,602,116► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-003Jul 13, 20095,602,116► Subscribe
Genzyme Corp
HECTOROL
doxercalciferol
CAPSULE;ORAL020862-001Jun 9, 19995,869,473► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GENZYME CORP drugs

Drugname Dosage Strength Tradename Submissiondate
doxercalciferol
Injection2 mcg/mL, 1 mL in 2 mL vial
HECTOROL
12/28/2011
doxercalciferol
Capsules1 mcg
HECTOROL
2/12/2010
doxercalciferol
Capsules0.5 mcg and 2.5 mcg
HECTOROL
3/25/2009
doxercalciferol
Injection2 mcg/mL, 2 mL ampules
HECTOROL
10/15/2007

Non-Orange Book Patents for Genzyme Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,265,228Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
6,040,332 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,051,598 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
5,916,911 Amino ceramide--like compounds and therapeutic methods of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Genzyme Corp Drugs

Country Document Number Estimated Expiration
TaiwanI355269► Subscribe
South Korea20000048572► Subscribe
Hong Kong1132267► Subscribe
Saudi Arabia2139► Subscribe
Austria555102► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Genzyme Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0036France► SubscribePRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119
2015000051Germany► SubscribePRODUCT NAME: ELIGLUSTAT, GGF. IN FORM EINES PHYSIOLOGISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
2012015,C1244647Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
2012000057Germany► SubscribePRODUCT NAME: VANDETANIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
90028-8Sweden► SubscribePRODUCT NAME: VANDETANIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/11/749/001 20120217
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Fish and Richardson
Teva
Farmers Insurance
Julphar
US Army
Argus Health
Cantor Fitzgerald
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot